equisights

Steel Dynamics (NASDAQ:STLD) Increases Quarterly Dividend by 25% Demonstrating Strong Financial Position and Commitment to Shareholders

Leave a Comment / Trending Tickers /

[vc_row][vc_column][vc_column_text]Steel Dynamics (NASDAQ:STLD) has announced a significant increase in its quarterly dividend, demonstrating the company\’s commitment to its shareholders and highlighting its strong financial position. The company declared a quarterly dividend of $0.425 per share, representing a 25% increase from its previous dividend of $0.340 per share. The increased dividend payout is a testament to […]

Steel Dynamics (NASDAQ:STLD) Increases Quarterly Dividend by 25% Demonstrating Strong Financial Position and Commitment to Shareholders Read More »

Victory Capital\’s AUM falls 2.3% in February

Leave a Comment / Trending Tickers /

[vc_row][vc_column][vc_column_text]Victory Capital Holdings, Inc. (NASDAQ: VCTR) reported that its assets under management (AUM) fell 2.3% from January to $157.7 billion as of February 28. However, average AUM increased to $160.2 billion from $157.1 billion in the previous month. The decline in AUM was seen across several asset classes. Solutions AUM dropped 3.3% month-over-month to $52.84

Victory Capital\’s AUM falls 2.3% in February Read More »

Wheaton Precious Metals misses Q4 earnings estimates, revenue falls YoY

Leave a Comment / Trending Tickers /

[vc_row][vc_column][vc_column_text]Wheaton Precious Metals Corp. (NYSE: WPM) reported its Q4 earnings on Thursday, with revenue falling YoY and missing estimates. The company\’s Q4 Non-GAAP EPS was $0.23, missing estimates by $0.02, while revenue came in at $236.05 million, missing estimates by $5.65 million. The company\’s revenue decline was attributed to lower sales volumes due to lower

Wheaton Precious Metals misses Q4 earnings estimates, revenue falls YoY Read More »

Pliant Therapeutics Reports Q4 2022 Financial Results, Misses on EPS but Beats on Revenue

Leave a Comment / AI /

[vc_row][vc_column][vc_column_text]Pliant Therapeutics (NASDAQ: PLRX) reported its fourth quarter results on Thursday, with a GAAP loss per share of $0.72, missing analysts\’ expectations by $0.02. However, the company\’s revenue of $1.97 million, down 1.5% year-over-year, beat expectations by $0.8 million. Pliant Therapeutics is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing novel treatments

Pliant Therapeutics Reports Q4 2022 Financial Results, Misses on EPS but Beats on Revenue Read More »

Molekule to Acquire Aura Smart Air for $10M in All-Stock Merger

Leave a Comment / Trending Tickers /

[vc_row][vc_column][vc_column_text]Molekule, a San Francisco-based air purification company, has announced a definitive agreement to acquire Aura Smart Air, a listed Israeli company specializing in smart air technology. The all-stock merger, valued at approximately $10 million, will see Molekule acquire Aura for a purchase price of around 3.5 million shares. Aura\’s patented smart air technology platform is

Molekule to Acquire Aura Smart Air for $10M in All-Stock Merger Read More »

Nano Dimension Offers to Acquire Stratasys for $18 a Share

Leave a Comment / Trending Tickers /

[vc_row][vc_column][vc_column_text]Israel-based 3D printing company Nano Dimension (NASDAQ:NNDM) has made an unsolicited offer to acquire its rival Stratasys (NASDAQ:SSYS) for $18 per share in cash, representing a 36% premium to Stratasys\’s closing price on March 1 and a 29% premium to Thursday\’s closing price. Stratasys, which confirmed receipt of the offer, surged 14% in after-hours trading,

Nano Dimension Offers to Acquire Stratasys for $18 a Share Read More »

Poseida Therapeutics Reports Disappointing Q4 Results with Missed Revenue and EPS

Leave a Comment / AI /

[vc_row][vc_column][vc_column_text]Poseida Therapeutics, a biotechnology company focused on developing gene therapies for cancer and other genetic diseases, reported disappointing Q4 2022 results on Thursday. The company\’s Q4 GAAP earnings per share (EPS) came in at -$0.39, missing expectations by $0.56. Meanwhile, revenue for the quarter was $10.05 million, down 67.8% year-over-year and missing estimates by $21.7

Poseida Therapeutics Reports Disappointing Q4 Results with Missed Revenue and EPS Read More »

Ready Capital and Broadmark Realty Capital Announce Merger to Create $2.8 Billion Commercial Mortgage REIT

Leave a Comment / Trending Tickers /

[vc_row][vc_column][vc_column_text]Ready Capital and Broadmark Realty Capital have announced a definitive merger deal that will create the fourth-largest commercial mortgage REIT with a capital base of $2.8 billion. Both Ready Capital (NYSE:RC) and Broadmark Realty Capital (NYSE:BRMK) are real estate finance companies that provide loans to businesses and investors. Ready Capital focuses on small and middle-market

Ready Capital and Broadmark Realty Capital Announce Merger to Create $2.8 Billion Commercial Mortgage REIT Read More »

Walgreens\’ $54M Contract with California to be Canceled Over Abortion Pill Access

Leave a Comment / AI /

[vc_row][vc_column][vc_column_text]Walgreens Boots Alliance (NASDAQ: WBA) is set to lose a $54M contract with California following the company\’s decision not to sell abortion pills in certain states. The contract, which provides specialty prescription drugs primarily to the California Department of Corrections and Rehabilitation and its correctional healthcare system, is set to expire on April 30. In

Walgreens\’ $54M Contract with California to be Canceled Over Abortion Pill Access Read More »

Scroll to Top